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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Corneal proliferative angiogenesis is an
orphan disease leading to cornea loss.
￿ Today’s therapeutic approach is not clearly
established,although essentially based on
topical corticosteroids.
￿ There is therefore a need for new
therapeutic alternatives speciﬁcally
targeting angiogenesis.
WHAT THIS PAPER ADDS
￿ Preclinical data demonstrated the efﬁcacy of
GS-101,an antisense oligonucleotide
inhibiting insulin receptor substrate-1
expression,at inhibiting experimental
corneal angiogenesis.
￿ This study demonstrates the excellent safety
and tolerability proﬁle of GS-101 applied as
eye drops three times daily in this
‘ﬁrst-in-man’study.
￿ Upon validation in human of its immediate
beneﬁt,GS-101 would offer an alternative to
antivascular endothelial growth factor
therapies in the treatment of corneal
angiogenesis.
AIMS
GS-101 (GeneSignal,Epalinges,Switzerland) is an antisense oligonucleotide
that inhibits the expression of the scaffold protein insulin receptor
substrate-1 (IRS-1).Inhibition of IRS-1 results in the prevention of
neovascular growth and was shown to prevent the angiogenic process in
preclinical in vitro and in vivo experiments.There is therefore a strong
therapeutic rational for targeting angiogenesis in pathological
neovascularization.We aimed to investigate the safety,tolerability and
bioavailability of GS-101 eye drops.
METHODS
This was a Phase I open-label study.The investigation was performed in
two steps.Local ocular tolerability was ﬁrst assessed with the application of
one single low dose in one eye.After no signs of intolerance were observed
in the subjects,the dose escalation phase of the study was initiated,and
the remaining subjects received three times daily escalating doses of
GS-101 in one eye for 14 days.
RESULTS
The 14 healthy volunteers tolerated well 14 days’ continued use of
escalating doses of GS-101 from 43 to 430 mg per day.Other than itching,
experienced also in the control eye by one subject and determined to be
unrelated to the study treatment,no signs of intolerance were observed.
CONCLUSIONS
The tolerability proﬁle obtained from this study suggests that GS-101
is safe for human use.Further clinical evaluations in diseases related
to abnormal angiogenesis are being targeted.In particular,the
neovascularization-related orphan indications of corneal graft rejection,
retinopathy of pre-maturity and neovascular glaucoma are currently under
Phase II clinical investigation and are showing promising results.
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Angiogenesisisafundamentalaspectofmanynormaland
abnormal biological processes.Wound healing,embryonic
development and the menstrual cycle are examples of
normal angiogenesis. Both excessive and insufﬁcient
angiogenesis can be pathological. Insufﬁcient angiogen-
esis can lead to stroke, heart disease, ulcers, infertility or
scleroderma,whereasexcessiveangiogenesisisattheroot
of rheumatoid arthritis,psoriasis,cancer and certain forms
of blindness [1–4].
Insulin receptor substrate 1 (IRS-1) is a cytoplasmic
docking protein that functions as an essential signalling
intermediate downstream of activated cell surface recep-
tors, including insulin, insulin-like growth factor 1 (IGF-1),
prolactin, growth hormone, vascular endothelial growth
factor (VEGF) receptors,members of the integrin receptor
family,and select cytokine receptors [5–9].IRS-1 was origi-
nally identiﬁed as a substrate of the insulin receptor,and it
has been predominantly studied for its role in metabolic
signalling [9].The role of IRS-1 in angiogenesis stems from
the fact that insulin and IGF systems have been implicated
in several vascular diseases, including angiogenesis [10].
IRS-1 could mediate the regulation of VEGF [11] or other
proangiogenic cytokines [12]. Mice knockout for IRS-1
gene expression develop less neovascularization [13].
There is therefore a strong therapeutic rationale for target-
ingIRS-1inhibitionwhereexcessiveangiogenesisispartof
the pathological process [14–16].
GS-101 (GeneSignal,Epalinges,Switzerland) is a 25mer
phosphorothioate antisense oligonucleotide with a
molecular mass of 8036 Da (5′-TATCCGGAGGGCTCGC
CATGCTGCT-3′). GS-101 inhibits the expression of IRS-1
[17]. This inhibition of IRS-1 results in the prevention of
neovascular growth and has been reported to prevent the
angiogenicprocessinpreclinicalinvivoandinvitroexperi-
ments [17, 18]. Speciﬁcally, the neovascularization-related
orphan indications of corneal graft rejection, retinopathy
of pre-maturity and neovascular glaucoma are being tar-
geted as initial clinical applications of GS-101.This safety,
tolerability and bioavailability investigation is the ﬁrst step
in the development of GS-101 as a novel antiangiogenic
therapeutic agent.
Materials and methods
The study protocol and the patient informed consent form
were approved by an independent Ethics Committee
(Ethische Kommission Beider Basel) and by the Swiss
Health Authorities (Swissmedic) prior to starting the study.
The study was conducted according to the Declaration of
HelsinkiIIIandinaccordancewiththeInternationalEthical
Guidelines for Biomedical Research Involving Human Sub-
jects as laid down by the Council for International Organi-
zationsofMedicalSciencesincollaborationwiththeWorld
Health Organization and the Good Clinical Practice guide-
line CPMP/ICH/135/95.
Good manufactory practice batches of GS-101 were
provided by the company Gene Signal Interational
SA (Epalinges, Switzerland ; patents US#7,417,033;
EP#1,409,672;CA#2,451,874).GS-101 was re-suspended in
sterile saline solution (0.9% NaCl) daily at room tempera-
ture and was used as such. Each drop of GS-101 solution
was calibrated to a volume of 50 ml.
Protocol design
This‘ﬁrst-in-man’PhaseIopen-labelstudywasdesignedto
investigate the safety, tolerability and bioavailability of
GS-101 eye drops.The investigation was performed in two
steps. Local ocular tolerability was ﬁrst assessed in three
subjects with the application of one drop (14.3 mgp e r
drop) three times per day in one eye only,for a total dose
per day of 43 mg. After no signs of intolerance or adverse
events were observed in these subjects after 3 days, the
same application was applied a second time,and the sub-
jects were followed for another three consecutive days.
After no signs of intolerance or adverse events were
observed in these subjects after the second 3-day obser-
vational period, the dose-escalation phase of the study
began. The dose regimen was as described in Figure 1.
Twelve volunteers received three times daily escalating
doses of GS-101 in one eye over a 14-day period.The study
drug was administered by eye drops of 50 ml in one eye
only;thesecondeyewasmonitoredasthecontroleye.The
eyeassignedtotreatmentwasnotrandomizedbutchosen
by the volunteer. The control eye did not receive the
vehicle (sterile NaCl 0.9% solution) following the scientiﬁc
committee recommendations.
As presented in Figure 1, the ﬁrst three doses were
administeredfor2daysbeforemovingtotheseconddose.
The fourth dose was therefore administered for the last 7
days of the study. All volunteers received three drops per
day of 14.3 mg (43 mgd a y
-1, days 1 and 2), 28.7 mg (86 mg
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Figure 1
Dose regimen followed during the study. The initial three doses were
applied on two consecutive days, whereas the highest dose tested was
applied for the remaining 8 days
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-1, days 3 and 4), 86.0 mg (258 mgd a y
-1, days 5 and 6),
and 143.3 mg (430 mgd a y
-1, days 7 to 14). Subjects were
followed up for an additional 7–10 days after the last eye
drop administration in order to assess possible delayed
adverse side-effects.
The medical and nursing staff of the Clinical Research
Centre of the University Hospital Basel assessed ocular
(local) tolerability every day, three times a day before eye
drop instillation.Local ocular tolerability was examined for
the following solicited symptoms:irritation,redness of the
eye, sensation of burning, blurred vision, eye watering. In
addition, a slit lamp examination was performed daily.
Safetyassessmentsforlocaltolerabilityweremadedailyby
the investigator at baseline and at the time of adverse
events during the whole duration of the study (14 days),at
study end and at follow-up (between 7 and 10 days after
end of treatment).
Assessment of clinical tolerability
Assessment of tolerability was obtained through a com-
plete medical history evaluation of past or present cardio-
vascular, respiratory, gastrointestinal, renal, hepatic,
neurological,endocrine,lymphatic,haematological,immu-
nological, dermatological, psychiatric, genitourinary, and
surgical history or any other diseases or disorders. Any
currently active medication was recorded.Physical exami-
nations was performed and included an examination of
general appearance, body weight, head, eyes, ears, nose
and throat, neck, skin, cardiovascular system, respiratory
system, abdominal system, nervous system. Vital signs
[blood pressure and pulse rate (supine after 3 min rest and
standing position after 1 min of standing) and body
temperature] were recorded. Computerized 12-lead ECG
recordings were obtained (rhythm, ventricular rate, PR
interval,QRS duration and QT/QTc).
Assessment of biological tolerability was performed at
baseline and at end of treatment using clinical laboratory
tests.Haematology tests included full blood count includ-
ing red blood cell count, haemoglobin, haematocrit,
packed cell volume, mean corpuscular volume, mean cell
haemoglobin, mean cell haemoglobin concentration,
white blood cell count and differential white cell count.
Coagulation tests included activated partial thromboplas-
tin time and prothrombin time and International Nor-
malized Ratio. Serum biochemistry included sodium,
potassium, creatinine, urea, alanine amino transaminase,
aspartate amino transaminase, bilirubin, uric acid, total
protein, triglycerides, cholesterol, calcium and glucose
(fasting).Urinalysis included pH,protein,glucose,ketones,
urobilirubin,blood,speciﬁc gravity and leucocytes.Screen
for drug abuse (cannabis and metabolites, cocaine and
metabolites, amphetamines, opiates) and alcohol were
performed at the discretion of the investigator.Viral serol-
ogyincludedhepatitisBsurfaceantigenandanti-hepatitis
C virus and HIV.
Plasma quantiﬁcation of GS-101
We used the ultrasensitive noncompetitive hybridization
method described by Yu and colleagues [19] and able to
detect 0.1–1.0 nM of phosphorothioate oligodeoxynucle-
otides in plasma, in order to evaluate the potential
bioavailability of GS-101 in plasma following topical appli-
cationintheeye.Intra-assay,interassayprecisionandaccu-
racy were determined by the analysis of quality control
samples at low (25 pM), intermediate (100 pM) and high
(500 pM) concentration levels.The interindividual variabil-
ity,evaluated with samples from ﬁve subjects,was 9.2% at
500 pM.The calibration curve was done in human plasma
between 7.81 and 1000 pM and was ﬁtted with a cubic
spline algorithm. The intra-assay mean precision (repeat-
ability), calculated with the three quality control samples,
was 10.8%,the interassay mean precision (reproducibility)
was 17.0% and the accuracy was comprised in
a range of 100  30% for these three quality-control
samples. The limit of quantiﬁcation with acceptable reli-
ability and accuracy (30% and 70–130%, respectively)
was deﬁned at 25 pM and the limit of detection was deter-
minedat20.5 pM.GS-101wasfoundtobestableinhuman
plasma in the tested assay conditions, after at least three
freeze–thawcyclesandafterstorageforabout2monthsat
-20°C and -80°C.
Results
Between 24 June 2004 and 23 August 2004, 14 healthy
male volunteers aged between 22 and 39 years (mean 29
 6) were enrolled in this Phase I clinical evaluation.In the
ﬁrstphaseofthisstudy,nosignsofocularintolerancewere
observed and no adverse reactions were reported in the
ﬁrst three treated subjects. One subject discontinued the
study prematurely during the ﬁrst phase due to family
reasons and was not available for the last two ophthalmo-
logical observations.However,he did return for the end of
study examination,which revealed no signs of intolerance.
Basedontheresultsoftheﬁrstthreesubjects’initialuseof
low-dose GS-101,it was decided to continue with the dose
escalation phase of the study (Figure 1).
Adverse events were recorded and summarized in
Table 1.Tenadversereactions(sevenmild,threemoderate)
were reported in six patients.Bilateral itching,probably of
allergicorigin,andadullfeelingofpressurewereobserved
in two of the 12 subjects during the ocular intolerance
assessment of the dose escalating period. Mild to moder-
ate itching in the treated eye was reported to the study
nurse by two subjects on three occasions as reported
during the ocular intolerance examination. Bilateral itch-
ing,also in the control eye,was reported in one additional
volunteer.Mild to moderate headache was reported twice
by one subject. Dull pressure of mild intensity in the
treated eye was reported by two subjects as also reported
duringtheocularintoleranceexamination.Inaddition,one
GS-101 eye drop tolerability
Br J Clin Pharmacol / 68:2 / 171subjectpresentedsignsofacommoncoldandonesubject
reportedmuscularpainonthedayfollowingthelastdayof
eye drop treatment. All events resolved and were deter-
mined to be unrelated to the study treatment.No serious
adverse events were reported, and in no case was the
study treatment interrupted.
No changes or abnormalities were observed in the
ocularexaminationincludingvisualacuity,slitlampexami-
nation,eyefundusandintraocularpressuremeasurements
performedatscreeningandaftertheendofthetreatment.
No abnormalities were observed between the beginning
and end of treatment in the assessment of clinical toler-
ability. Physical examination, vital signs and 12-lead ECG
were all normal.Changes from baseline to end of study in
laboratory parameters are shown inTable 2.No abnormal-
ity was observed.
In ﬁve patients tested, GS-101 was not detectable in
the plasma 1.5 h after administration of one drop of the
highest concentration (143.3 mg per drop).
Discussion
The phenomenon of angiogenesis is complex and the
implications of excessive angiogenesis are huge. IRS-1
involvement in angiogenesis has been demonstrated in
vitro and in animal experiments,and the ability of GS-101
to inhibit IRS-1 has been validated [17,18].Previous in vitro
investigations have shown that GS-101 inhibits IRS-1
expression in human endothelial cells placed under differ-
ent angiogenic stimuli [17]. Partial IRS-1 inhibition by
GS-101inducedasigniﬁcantinhibitionofbothVEGF-Aand
interleukin-1btranscriptioninculturedhumanendothelial
cells associated with complete inhibition of capillary-like
tube formation [17], an in vitro model of angiogenesis.
Accordingly,topical administration of GS-101 in the injury-
induced corneal neovascularization rat model inhibited in
vivo angiogenesis [17, 18].The results of this ‘ﬁrst-in-man’
Table 1
Summary of adverse events (AEs) recorded during the study
AEs Number of patients
Itching of both eyes and dull feeling of pressure 2
Itching of both eyes 1
Itching in the treated eye 2
Feeling of dull pressure in the treated eye 2
Headache 1
Muscular pain 1
Common cold 1
Table 2
Changes from baseline to the end of the study in laboratory parameters,mean values
Parameter Unit BL n = 12 End n = 12 STD n = 24 Change BL to end
Haematology
Haemoglobin gd l -1 154 148 9.0 5.58
Haematocrit fraction 0.43 0.43 0.0 0.01
Erythrocytes 1012 l-1 5.0 4.8 0.4 0.19
Leucocytes 109 l-1 5.5 4.9 1.4 0.62
Neutrophils 109 l-1 2.9 2.8 0.7 0.09
Lymphocytes 109 l-1 1.9 1.8 0.4 0.10
Monocytes 109 l-1 0.30 0.32 0.1 0.02
Eosinophils 109 l-1 0.21 0.22 0.2 0.01
Platelets 109 l-1 242 243 40.6 1.42
Clinical chemistry
ALT Ul -1 21 18 7.4 2.67
AST Ul -1 21 22 5.7 0.67
Bilirubin mmol l-1 18 18 9.4 0.17
Alkaline phosphatase Ul -1 62 61 19.5 1.67
Albumin gl -1 43 43 1.8 0.67
Creatinine mmol l-1 87 84 9.3 3.00
Chloride mmol l-1 103 105 2.3 1.50
Sodium mmol l-1 140 139 2.2 1.42
Cholesterol total mmol l-1 4.8 4.4 1.8 0.43
Potassium mmol l-1 3.9 3.8 0.3 0.07
Gamma GT Ul -1 21 17 7.9 3.75
Glucose mmol l-1 4.7 4.6 0.4 0.10
HDL-cholesterol mmol l-1 1.4 1.4 0.2 0.05
Phosphate mmol l-1 1.1 1.0 0.2 0.04
Protein total gl -1 75 74 2.6 1.25
Blood urea mmol l-1 4.6 4.4 0.6 0.17
Uric acid mmol l-1 355 340 59.9 15.2
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein.
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strate that GS-101 is well tolerated in healthy human sub-
jects. A hybridization assay has been established and
validated for the detection of GS-101 in human plasma at
extremelylowlevels(20.5 pM);usingthisassay,GS-101was
not detectable in the plasma following GS-101 administra-
tion, strongly suggesting that it is essentially cleared and
degraded locally, therefore strongly limiting the possibili-
ties of systemic off-target effects.
Although the functional consequences of inhibiting
IRS-1 expression by GS-101 could be investigated further
in diseases where excessive angiogenesis is found,orphan
indications of corneal graft rejection, retinopathy of pre-
maturityandneovascularglaucomahavebeentargetedas
the ﬁrst indications for its potential clinical use.In a recent
Phase II clinical study of 40 patients with aggressive
corneal neovascularization and nonresponsive to con-
ventional therapy, GS-101 was reported to induce highly
signiﬁcant regression of corneal neovascularization
compared with the placebo group,where corneal neovas-
cularization progressed in all patients [20].
In conclusion, GS-101 eye drops are safe at the
maximum dose used in this study, i.e. 143.3 mg per drop,
three times daily. Further investigations in Phase II and III
clinical studies are needed for the development of GS-101
as a novel anti-angiogenic therapeutic agent.
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